Clinical Trial Update: RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for RP5063 in schizophrenia and schizoaffective disorder. The study completed and results were posted in January 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• RP5063

Snippet

Sponsor: Reviva Pharmaceuticals | Conditions: Acute Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED | Results posted: 2015-01-26